Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Roche announced that the FDA granted Breakthrough Therapy Designation to Genentech's Inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation. The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared to palbociclib and fulvestrant alone.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 5:32 am

Roche's Genentech reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity, showing significant weight loss and glycemia normalization with no new safety concerns.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 6:13 am

HOOKIPA Pharma Inc (NASDAQ:HOOK) saw its stock rise after receiving FDA clearance for its IND application for HB-700, a vaccine targeting KRAS-mutated cancers. Despite Roche (OTC:RHHBY) ending their collaboration earlier, HOOKIPA will regain full control of the HB-700 program's IP in April 2024. The company also plans to present preclinical data at the ASCO 2024 Annual Meeting. Additionally, HOOKIPA is focusing on its HB-200 program and partnerships with Gilead Sciences Inc (NASDAQ:GILD) for infectious disease cures.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 2:31 pm

Roche Holdings AG announced positive Phase 3 results for its lymphoma drug Columvi in combination with chemotherapy, showing extended survival in pretreated patients with diffuse large B-cell lymphoma. The study met its primary endpoint of overall survival. Columvi, a bispecific antibody, previously received FDA accelerated approval for this patient group after two or more lines of systemic therapy. Additionally, Roche terminated two cancer drug deals earlier this year with Repare Therapeutics and HOOKIPA Pharma.

Portfolio Pulse from Vandana Singh

April 15, 2024 | 12:56 pm

Roche's Genentech announced that its drug Columvi, in combination with chemotherapy, met its primary endpoint of overall survival in a Phase III STARGLO study for patients with relapsed or refractory diffuse large B-cell lymphoma. The results, showing a statistically significant improvement in survival, will be submitted to health authorities and presented at an upcoming medical meeting.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 5:34 am

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented mixed results from the KARDIA-2 Phase 2 study of zilebesiran for hypertension, showing efficacy with indapamide and amlodipine but not with olmesartan. Despite this, analysts from JMP Securities and William Blair express confidence in the drug's potential, recommending ALNY shares with an Overweight rating and a price target of $217. Alnylam, in partnership with Roche Holdings AG (OTC:RHHBY), is advancing zilebesiran into further trials. ALNY shares rose 2.46% to $157.34.

Portfolio Pulse from Vandana Singh

April 08, 2024 | 6:37 pm

Argenx SE (NASDAQ:ARGX) shares surged due to Chugai Pharmaceutical's disappointing gMG trial results, boosting Argenx's market cap to $21.2 billion. Argenx's Vyvgart Hytrulo was FDA approved in June 2023 for gMG in adults, contributing to $1.2 billion in FY2023 revenues. Chugai's Enspryng failed to meet expectations in its Phase 3 LUMINESCE study for gMG, despite being developed with Roche Holdings AG (OTC:RHHBY). Johnson & Johnson (NYSE:JNJ) reported success in its Phase 3 VIVACITY study of nipocalimab for gMG.

Portfolio Pulse from Vandana Singh

March 21, 2024 | 3:06 pm

The FDA approved BeiGene Ltd's Tevimbra for esophageal cancer, marking its first U.S. approval. Tevimbra, developed from BeiGene's immuno-oncology program, is for patients with unresectable or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The approval is based on the RATIONALE 302 trial showing significant survival benefits. BeiGene regained rights to Tevimbra from Novartis AG in September 2023. Additionally, the FDA granted accelerated approval for BeiGene's Brukinsa in combination with Roche's Gazyva for follicular lymphoma.

Portfolio Pulse from Vandana Singh

March 15, 2024 | 5:01 pm

Roche has launched navify Analytics and navify Monitoring as part of its navify operational excellence solutions aimed at laboratories and point of care services. These tools are designed to provide operational insights to lab managers and point of care coordinators, helping to manage workflows more efficiently, reduce costs, and improve productivity. The combination of navify Analytics and navify Monitoring allows laboratories to operate more efficiently, maintain quality, and improve test turnaround times.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 7:11 am

Goldman Sachs highlights concerns over the U.S. stock market's heavy concentration in its largest tech stocks, suggesting a 'barbell approach' for investors to diversify. The top 10 U.S. stocks now represent 33% of the S&P 500 market cap, leading to market performance skew. The firm also sees investment opportunities in Japan and the healthcare sector, and highlights European GRANOLAS stocks for their lower valuations and solid performance.

Portfolio Pulse from Piero Cingari

March 11, 2024 | 2:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.